Ongoing Projects

HOME > R&D Pipeline > Current status > Ongoing Projects

KDDF-201904-20 Development of Novel Hyaluronidase for the Subcutaneous Administration of Antibody Therapeutics(Others, Protein) [2019-11-26]

PRINT
Ongoing Project
Section Lead
Generation
Lead
Optimization
Preclinical Phase I Phase II Phase III

Development and Market Objectives

- Development of novel recombinant human hyaluronidase which can facilitate of large volume subcutaneous drug delivery esp. for immunoglobulins and anti-cancer monoclonal antibody therapeutics by degrading hyaluronan and promoting dispersion and absorption of administered fluid

- Improved structural stability and enzymatic activity by modifying human hyaluronidase PH20.

Unmet Medical Need & Target Patients

-  Applicable to any protein/antibody therapeutics which could be developed for SC administration

-  More emphasis on patient convenience in recent therapeutics market

-  SC administration is predominantly preferred to IV administration in terms of treatment time, cost, and patient convenience.

Status

- Stable cell line was established.

- Production process development for large scale production is ongoing.

- Preclinical animal study will soon be initiated.

Intellectual Property

- Patent #: 10-2018-00***** (application date: 2018. 07. 25)

- Patent #: 10-2019-00***** (application date: 2019. 03. 15)

Competitive Advantages

- Higher specific activity, stability and productivity than the wild-type PH20 and rHuPH20
- The only second recombinant human hyaluronidases in the market
 

Contact & Company Overview

Related Project

Related Project
list
Update to 2013 © KOREA DRUG DEVELOPMENT FUND. ALL RIGHTS RESERVED. QR Code